41 – 50 of 54
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
(
- Contribution to journal › Article
-
Mark
Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous, Dose-Ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus
(
- Contribution to journal › Article
-
Mark
Headache in Systemic Lupus Erythematosus Results From a Prospective, International Inception Cohort Study
(
- Contribution to journal › Article
- 2012
-
Mark
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
(
- Contribution to journal › Article
-
Mark
In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus
(
- Contribution to journal › Article
-
Mark
Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus
(
- Contribution to journal › Article
- 2011
-
Mark
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Ten years with biologics: to whom do data on effectiveness and safety apply?
(
- Contribution to journal › Article
- 2010
-
Mark
Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level.
(
- Contribution to journal › Article